Centogene reports second quarter and first half 2022 financial results

Cambridge, mass. and rostock, germany and berlin, dec. 22, 2022 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the second quarter and first half ended june 30, 2022 and updated its fiscal year 2022 financial outlook. the quarterly and half year results are compared to the same periods in the prior year, unless otherwise specified, and reflect revisions as described below.
CNTG Ratings Summary
CNTG Quant Ranking